{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:56:19Z","timestamp":1784260579392,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00228-024-03666-w","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T08:45:39Z","timestamp":1710405939000},"page":"813-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacokinetics of polymyxin B in different populations: a systematic review\u00a0"],"prefix":"10.1007","volume":"80","author":[{"given":"Xing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolian","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"issue":"4060","key":"3666_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/160263a0","volume":"159","author":"GC Ainsworth","year":"1947","unstructured":"Ainsworth GC, Brown AM, Brownlee G (1947) Aerosporin, an antibiotic produced by Bacillus aerosporus Greer. Nature 159(4060):263. https:\/\/doi.org\/10.1038\/160263a0","journal-title":"Nature"},{"issue":"9","key":"3666_CR2","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1128\/AAC.00013-14","volume":"58","author":"QY Lin","year":"2014","unstructured":"Lin QY et al (2014) Serratia marcescens arn, a PhoP-regulated locus necessary for polymyxin B resistance. Antimicrob Agents Chemother 58(9):5181\u20135190. https:\/\/doi.org\/10.1128\/AAC.00013-14","journal-title":"Antimicrob Agents Chemother"},{"key":"3666_CR3","doi-asserted-by":"publisher","first-page":"679109","DOI":"10.1155\/2015\/679109","volume":"2015","author":"Z Yu","year":"2015","unstructured":"Yu Z et al (2015) Antibacterial mechanisms of polymyxin and bacterial resistance. Biomed Res Int 2015:679109. https:\/\/doi.org\/10.1155\/2015\/679109","journal-title":"Biomed Res Int"},{"issue":"7195","key":"3666_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s0140-6736(61)90464-0","volume":"2","author":"HE Clifford","year":"1961","unstructured":"Clifford HE, Stewart GT (1961) ntraventricular administration of a new derivative of polymyxin B in meningitis due to Ps. pyocyanea. Lancet 2(7195):177\u201380. https:\/\/doi.org\/10.1016\/s0140-6736(61)90464-0","journal-title":"Lancet"},{"key":"3666_CR5","first-page":"89","volume":"7","author":"S Ross","year":"1959","unstructured":"Ross S, Puig JR, Zaremba EA (1959) Colistin: some preliminary laboratory and clinical observations in specific gastroenteritis in infants and children. Antibiot Annu 7:89\u2013100","journal-title":"Antibiot Annu"},{"issue":"4","key":"3666_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.diagmicrobio.2010.10.013","volume":"69","author":"EA Neuner","year":"2011","unstructured":"Neuner EA et al (2011) Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis 69(4):357\u2013362. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2010.10.013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"12","key":"3666_CR7","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","volume":"30","author":"LM Lim","year":"2010","unstructured":"Lim LM et al (2010) Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30(12):1279\u20131291. https:\/\/doi.org\/10.1592\/phco.30.12.1279","journal-title":"Pharmacotherapy"},{"issue":"1","key":"3666_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT et al (2019) International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 39(1):10\u201339. https:\/\/doi.org\/10.1002\/phar.2209","journal-title":"Pharmacotherapy"},{"issue":"10","key":"3666_CR9","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1086\/592577","volume":"47","author":"AP Zavascki","year":"2008","unstructured":"Zavascki AP et al (2008) Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47(10):1298\u20131304. https:\/\/doi.org\/10.1086\/592577","journal-title":"Clin Infect Dis"},{"issue":"11","key":"3666_CR10","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1128\/AAC.01244-15","volume":"59","author":"KY Seng","year":"2015","unstructured":"Seng KY et al (2015) Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers. Antimicrob Agents Chemother 59(11):6791\u20136799. https:\/\/doi.org\/10.1128\/AAC.01244-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3666_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2478\/jtim-2019-0022","volume":"7","author":"H Spapen","year":"2019","unstructured":"Spapen H et al (2019) Treatment of ventilator-associated pneumonia with high-dose colistin under continuous veno-venous hemofiltration. J Transl Int Med 7(3):100\u2013105. https:\/\/doi.org\/10.2478\/jtim-2019-0022","journal-title":"J Transl Int Med"},{"issue":"7","key":"3666_CR12","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/phar.2129","volume":"38","author":"SN Avedissian","year":"2018","unstructured":"Avedissian SN et al (2018) Polymyxin B pharmacokinetics in adult cystic fibrosis patients. Pharmacotherapy 38(7):730\u2013738. https:\/\/doi.org\/10.1002\/phar.2129","journal-title":"Pharmacotherapy"},{"key":"3666_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3389\/fphar.2020.00829","volume":"11","author":"P Wang","year":"2020","unstructured":"Wang P et al (2020) Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant gram-negative bacterial infections. Front Pharmacol 11:829. https:\/\/doi.org\/10.3389\/fphar.2020.00829","journal-title":"Front Pharmacol"},{"key":"3666_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01900-20","author":"P Wang","year":"2021","unstructured":"Wang P et al (2021) Comparing the population pharmacokinetics of and acute kidney injury due to polymyxin b in chinese patients with or without renal insufficiency. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01900-20","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3666_CR15","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1111\/bcp.14576","volume":"87","author":"XB Yu","year":"2021","unstructured":"Yu XB et al (2021) Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions. Br J Clin Pharmacol 87(4):1869\u20131877. https:\/\/doi.org\/10.1111\/bcp.14576","journal-title":"Br J Clin Pharmacol"},{"key":"3666_CR16","doi-asserted-by":"publisher","first-page":"727170","DOI":"10.3389\/fphar.2021.727170","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y et al (2021) Population pharmacokinetics of polymyxin B and dosage optimization in renal transplant patients. Front Pharmacol 12:727170. https:\/\/doi.org\/10.3389\/fphar.2021.727170","journal-title":"Front Pharmacol"},{"key":"3666_CR17","doi-asserted-by":"publisher","first-page":"106214","DOI":"10.1016\/j.ejps.2022.106214","volume":"175","author":"X Luo","year":"2022","unstructured":"Luo X et al (2022) Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with\/without continuous renal replacement therapy. Eur J Pharm Sci 175:106214. https:\/\/doi.org\/10.1016\/j.ejps.2022.106214","journal-title":"Eur J Pharm Sci"},{"key":"3666_CR18","doi-asserted-by":"publisher","first-page":"1019411","DOI":"10.3389\/fphar.2022.1019411","volume":"13","author":"XJ Cai","year":"2022","unstructured":"Cai XJ et al (2022) Population pharmacokinetic analysis, renal safety, and dosing optimization of polymyxin B in lung transplant recipients with pneumonia: A prospective study. Front Pharmacol 13:1019411. https:\/\/doi.org\/10.3389\/fphar.2022.1019411","journal-title":"Front Pharmacol"},{"issue":"10","key":"3666_CR19","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1111\/jcpt.13711","volume":"47","author":"Q Ye","year":"2022","unstructured":"Ye Q et al (2022) The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation. J Clin Pharm Ther 47(10):1608\u20131618. https:\/\/doi.org\/10.1111\/jcpt.13711","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"3666_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/cid\/cit334","volume":"57","author":"AM Sandri","year":"2013","unstructured":"Sandri AM et al (2013) Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57(4):524\u2013531. https:\/\/doi.org\/10.1093\/cid\/cit334","journal-title":"Clin Infect Dis"},{"issue":"11","key":"3666_CR21","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1093\/jac\/dkac265","volume":"77","author":"PL Wang","year":"2022","unstructured":"Wang PL et al (2022) Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother 77(11):3000\u20133008. https:\/\/doi.org\/10.1093\/jac\/dkac265","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"3666_CR22","doi-asserted-by":"publisher","first-page":"e0079221","DOI":"10.1128\/AAC.00792-21","volume":"65","author":"RL Crass","year":"2021","unstructured":"Crass RL et al (2021) Pharmacokinetics of polymyxin B in hospitalized adults with cystic fibrosis. Antimicrob Agents Chemother 65(10):e0079221. https:\/\/doi.org\/10.1128\/AAC.00792-21","journal-title":"Antimicrob Agents Chemother"},{"key":"3666_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01475-17","author":"C Miglis","year":"2018","unstructured":"Miglis C et al (2018) Population pharmacokinetics of polymyxin B in acutely ill adult patients. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01475-17","journal-title":"Antimicrob Agents Chemother"},{"key":"3666_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01493-17","author":"CJ Kubin","year":"2018","unstructured":"Kubin CJ et al (2018) Population pharmacokinetics of intravenous polymyxin B from clinical samples. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01493-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3666_CR25","doi-asserted-by":"publisher","first-page":"106599","DOI":"10.1016\/j.ijantimicag.2022.106599","volume":"60","author":"P Wang","year":"2022","unstructured":"Wang P et al (2022) Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration. Int J Antimicrob Agents 60(1):106599. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106599","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"3666_CR26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/jac\/dkad012","volume":"78","author":"MY Pi","year":"2023","unstructured":"Pi MY et al (2023) Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients. J Antimicrob Chemother 78(3):792\u2013801. https:\/\/doi.org\/10.1093\/jac\/dkad012","journal-title":"J Antimicrob Chemother"},{"issue":"5\u20136","key":"3666_CR27","doi-asserted-by":"publisher","first-page":"106693","DOI":"10.1016\/j.ijantimicag.2022.106693","volume":"60","author":"P Wang","year":"2022","unstructured":"Wang P et al (2022) Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 60(5\u20136):106693. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106693","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"3666_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00228-022-03415-x","volume":"79","author":"YA Surovoy","year":"2023","unstructured":"Surovoy YA et al (2023) Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis. Eur J Clin Pharmacol 79(1):79\u201387. https:\/\/doi.org\/10.1007\/s00228-022-03415-x","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"3666_CR29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/cpt.981","volume":"104","author":"P Manchandani","year":"2018","unstructured":"Manchandani P et al (2018) Population pharmacokinetics of polymyxin B. Clin Pharmacol Ther 104(3):534\u2013538. https:\/\/doi.org\/10.1002\/cpt.981","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"3666_CR30","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00228-021-03193-y","volume":"77","author":"YQ Li","year":"2021","unstructured":"Li YQ et al (2021) External evaluation of published population pharmacokinetic models of polymyxin B. Eur J Clin Pharmacol 77(12):1909\u20131917. https:\/\/doi.org\/10.1007\/s00228-021-03193-y","journal-title":"Eur J Clin Pharmacol"},{"key":"3666_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111814","author":"VH Tam","year":"2020","unstructured":"Tam VH et al (2020) Performance of population pharmacokinetic models in predicting polymyxin B exposures. Microorganisms. https:\/\/doi.org\/10.3390\/microorganisms8111814","journal-title":"Microorganisms"},{"issue":"2","key":"3666_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.diagmicrobio.2007.08.008","volume":"60","author":"AL Kwa","year":"2008","unstructured":"Kwa AL et al (2008) Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis 60(2):163\u2013167. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2007.08.008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3666_CR33","doi-asserted-by":"publisher","first-page":"754844","DOI":"10.3389\/fphar.2021.754844","volume":"12","author":"P Wang","year":"2021","unstructured":"Wang P et al (2021) Population pharmacokinetics of polymyxin B in obese patients for resistant gram-negative infections. Front Pharmacol 12:754844. https:\/\/doi.org\/10.3389\/fphar.2021.754844","journal-title":"Front Pharmacol"},{"key":"3666_CR34","doi-asserted-by":"publisher","first-page":"975066","DOI":"10.3389\/fphar.2022.975066","volume":"13","author":"Z Yu","year":"2022","unstructured":"Yu Z et al (2022) Pharmacokinetics\/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae. Front Pharmacol 13:975066. https:\/\/doi.org\/10.3389\/fphar.2022.975066","journal-title":"Front Pharmacol"},{"key":"3666_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112323","author":"X Li","year":"2022","unstructured":"Li X et al (2022) Evaluation and validation of the limited sampling strategy of polymyxin B in patients with multidrug-resistant gram-negative infection. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14112323","journal-title":"Pharmaceutics"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03666-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03666-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03666-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T07:05:46Z","timestamp":1715843146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03666-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3666"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03666-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]},"assertion":[{"value":"8 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}